Skip to main content

Table 2 Mean HbA1c values at randomization and at follow-up, in PARAGON-HF participants with diabetes, by treatment groups

From: Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials

 

Valsartan, n = 1184

Sacubitril/valsartan, n = 1211

Adjusted difference in change from randomization (95% CI)

P value

HbA1c (percent)

 Randomization

7.32 ± 1.43

7.37 ± 1.48

–

–

 Week 48

7.30 ± 1.57

7.10 ± 1.37

− 0.24 (− 0.33 to − 0.16)

< 0.001

 Week 96

7.17 ± 1.55

7.11 ± 1.46

− 0.12 (− 0.22 to − 0.01)

0.027

 Week 144

7.13 ± 1.46

7.08 ± 1.52

− 0.13 (− 0.26 to − 0.003)

0.044

  1. Between-group differences in changes from randomization were adjusted for randomization HbA1c values. Number of patients with HbA1c measurements at randomization: n = 2394 (val: n = 1183, sac/val: n = 1211), at week 48: n = 2143 (val: n = 1056, sac/val: n = 1087), at week 96: n = 1947 (val: n = 958, sac/val: n = 989), at week 144: n = 1378 (val: n = 693, sac/val: n = 685)
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840